Changes in plasma hormones and heart rate variability in patients receiving the cardiotoxic anti-cancer agent bevacizumab

Int J Cardiol. 2016 Sep 15:219:25-6. doi: 10.1016/j.ijcard.2016.05.061. Epub 2016 May 14.

¹ Department of Medicine, Queen's University, Kingston, Ontario, Canada; Section of Cardiology, Division of Internal Medicine, University of Manitoba, Winnipeg, Manitoba, Canada.
² Department of Medicine, Queen's University, Kingston, Ontario, Canada; Department of Cardiology, University of Calgary, Calgary, Canada.
³ Department of Medicine, Queen's University, Kingston, Ontario, Canada.
⁴ Department of Public Health Sciences, Queen's University, Kingston, Ontario, Canada.
⁵ Department of Medicine, Queen's University, Kingston, Ontario, Canada. Electronic address: barancha@kgh.kari.net.

No abstract available

Keywords: Autonomic nervous system; Cardio-oncology; Heart rate variability; Hypertension; Vascular endothelial growth factor.

Publication types